ORGANIC SPECTROSCOPY INTERNATIONAL: HCV NS5A Inhibitor from Theravance, Inc. to treat hepatitis C virus infection

.....

((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
N-[(1S)-1-[[(2S)-2-[5-[4'-[[[6-[(2R,5S) -2,5-dimethyl-4-[(methylamino)carbonyl]-1-piperazinyl]-3- pyridinyl]carbonyl]amino]-2'-(trifluoromethoxy)[1,1'-biphenyl]- 4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, Carbamic acid, methyl ester
Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4'-[[[6-[(2R,5S) -2,5-dimethyl-4-[(methylamino)carbonyl]-1-piperazinyl]-3- pyridinyl]carbonyl]amino]-2'-(trifluoromethoxy)[1,1'-biphenyl]- 4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester
CAS 1374883-22-3, 819.87, C₄₁ H₄₈ F₃ N₉ O₆
Theravance, Inc. INNOVATOR
To treat hepatitis C virus infection

((S)-1-{(S)-2-[4-(4′-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2′-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (compound 1):
Recent estimates place the number of people infected with the hepatitis C virus (HCV) worldwide at more than 170 million, including 3 million people in the United States. The infection rate is thought to be roughly 4 to 5 times that of the human immunodeficiency virus (HIV). While in some individuals, the natural immune response is able to overcome the virus, in the majority of cases, a chronic infection is established, leading to increased risk of developing cirrhosis of the liver and hepatocellular carcinomas. Infection with hepatitis C, therefore, presents a serious public health problem.

read at

http://newdrugapprovals.org/2015/11/03/hcv-ns5a-inhibitor-from-theravance-inc-to-treat-hepatitis-c-virus-infection/